Skincare company ZO Skin Health invited Aesthetics to celebrate the release of the Peptide Facial Refining Concentrate at The Delaunay, London on October 16.
The product was officially launched at the Clinical Cosmetic Regenerative Congress (CCR) and aims to address wrinkles and static lines while restoring facial volume, according to the company. The evening event commenced with general manager Brett Vye introducing the product and outlined ZO Skin Health’s objectives and vision.
Presentations detailed the formulation and intended effects, with speakers sharing that the product contains a combination of peptide refining concentrate, volumising tripeptide, Acetyl Octapeptide-3 and Acetyl-Hexapeptide-8, designed to target fine lines, facial geometry changes and volume loss.
The company also shared a clinical study conducted over the course of 12 weeks, involving 49 female participants aged between 47-72. The results indicated that 92% experienced a reduction in fine lines, 86% observed improvement in facial hollow areas and 96% reported smoother skin.
Brett Vye, general manager of ZO Skin Health UK&I, commented, “The launch of the new ZO Skin Health Peptide Facial Refining Concentrate was an incredible success. Our trainer, Melissa Lee, shared valuable insights into how this breakthrough formula enhances skin appearance and restores facial volume. Aesthetic practitioner Dr Saleena Zimir highlighted the remarkable visible improvements seen after just two weeks of use. With its clinically proven results, we’re confident this innovation will become one of the top 10 best-sellers for ZO UK and Ireland.”
